Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodyâs own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platformâs capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.

Employees

225

Sector

Biotechnology & Medical Research

Calendar

Feb. 18 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
26-01-13	74.13 $	+1.42%	668,165
26-01-12	73.09 $	-2.25%	785,599
26-01-09	74.77 $	-0.28%	594,820
26-01-08	74.98 $	-2.23%	744,868
26-01-07	76.69 $	+4.40%	929,828

Delayed Quote Nasdaq, January 13, 2026 at 04:00 pm EST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

74.13USD

Average target price

116.76USD

Spread / Average Target

+57.51%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-13 pm EST			5-day change	1st Jan Change
74.13 ^USD	+1.42%		+0.91%	-4.73%

Jan. 13	Kymera Therapeutics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 09:00 AM
Jan. 13	Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Portfolio of Oral Immunology Programs	CI

Capitalization	5.93B 5.1B 4.75B 4.42B 8.24B 536B 8.88B 54.63B 21.47B 256B 22.24B 21.78B 944B	P/E ratio 2025 *	-21.2x	P/E ratio 2026 *	-20.4x
Enterprise value	5.06B 4.35B 4.06B 3.77B 7.03B 457B 7.58B 46.64B 18.33B 219B 18.99B 18.6B 806B	EV / Sales 2025 *	94.9x	EV / Sales 2026 *	109x
Free-Float	98.65%	Yield 2025 *	-	Yield 2026 *	-

Jan. 13	Kymera Therapeutics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 09:00 AM
Jan. 13	Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Portfolio of Oral Immunology Programs	CI
Dec. 31	Kymera Therapeutics Insider Sold Shares Worth $2,341,939, According to a Recent SEC Filing	MT
Dec. 22	B. Riley Raises Price Target on Kymera Therapeutics to $117 From $80, Keeps Buy Rating	MT
Dec. 18	Kymera Therapeutics Insider Sold Shares Worth $2,264,480, According to a Recent SEC Filing	MT
Dec. 16	Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says	MT
Dec. 16	RBC Raises Price Target on Kymera Therapeutics to $103 From $70, Keeps Outperform, Speculative Risk	MT
Dec. 15	Kymera Therapeutics Insider Sold Shares Worth $21,699,044, According to a Recent SEC Filing	MT
Dec. 11	Kymera Therapeutics Says KT-621 Receives FDA Fast Track Designation in Atopic Dermatitis	MT
Dec. 11	Kymera Therapeutics announces U.S. FDA fast track designation for KT-621, a first-in-class, oral STAT6 degrader for the treatment of atopic dermatitis	RE
Dec. 11	Mizuho Raises Price Target on Kymera Therapeutics to $120 From $81, Keeps Outperform Rating	MT
Dec. 11	The U.S. Food and Drug Administration Has Granted Fast Track Designation to Kt-621, Its First-In-Class, Oral Stat6 Degrader	CI
Dec. 10	Kymera Therapeutics Prices $602 Million Common Share Offering	MT

Dec. 22	B. Riley Raises Price Target on Kymera Therapeutics to $117 From $80, Keeps Buy Rating	MT
Dec. 16	Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says	MT
Dec. 16	RBC Raises Price Target on Kymera Therapeutics to $103 From $70, Keeps Outperform, Speculative Risk	MT
Dec. 11	Mizuho Raises Price Target on Kymera Therapeutics to $120 From $81, Keeps Outperform Rating	MT
Dec. 09	Oppenheimer Adjusts Kymera Therapeutics PT to $120 From $67, Maintains Outperform Rating	MT

Kymera Therapeutics, Inc. Stock

Equities

KYMR

US5015751044

Biotechnology & Medical Research

Valuation: Kymera Therapeutics, Inc.

Chart: Kymera Therapeutics, Inc.

Latest news: Kymera Therapeutics, Inc.

Last Transcript: Kymera Therapeutics, Inc.

Analysts' recommendations: Kymera Therapeutics, Inc.

Press Releases: Kymera Therapeutics, Inc.

News in other languages: Kymera Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Kymera Therapeutics, Inc.

ETFs: Kymera Therapeutics, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Jan. 13	Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs	AQ
Jan. 06	Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13	AQ
Dec. 11	Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	AQ
Dec. 11	Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis	AQ
Dec. 09	Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering	AQ

Dec. 08	MÄRKTE USA/Anleger halten sich vor Zinsentscheid mit Käufen zurück
Dec. 08	Voorzichtige weekstart op Wall Street
Dec. 08	MÄRKTE USA/Vor Zinsentscheid macht sich Vorsicht breit
24-07-09	MÄRKTE USA/Erneute Rekorde - Powell-Aussagen setzen keinen Impuls
24-07-09	MÄRKTE USA/Rekordjagd geht weiter - Powell-Aussagen ohne Einfluss

1 day	+1.42%
1 week	+0.91%
Current month	-4.73%
1 month	-17.34%
3 months	+23.78%
6 months	+66.66%
Current year	-4.73%

1 week	71.46	77.92
1 month	69.08	90.33
Current year	69.08	77.92
1 year	19.44	103
3 years	9.6	103
5 years	9.6	103
10 years	9.6	103

Manager	Title	Age	Since
Nello Mainolfi CEO	Chief Executive Officer	47	2019-10-31
Bruce Jacobs DFI	Director of Finance/CFO	56	2019-07-14
Jeremy Chadwick COO	Chief Operating Officer	63	2023-05-21

Director	Title	Age	Since
Bruce Booth CHM	Chairman	51	2017-07-31
Nello Mainolfi BRD	Director/Board Member	47	2019-10-31
Gorjan Hrustanovic BRD	Director/Board Member	37	2020-02-29

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
KYMERA THERAPEUTICS, INC.	+1.42%	+0.91%	+99.17%	+114.62%	5.85B
LONZA GROUP AG	-0.92%	+4.28%	+2.98%	+14.36%	49.9B
IQVIA HOLDINGS INC.	+0.29%	+0.43%	+18.05%	+8.75%	41.02B
BEONE MEDICINES AG	+5.11%	+9.59%	+90.16%	+29.71%	36.96B
CELLTRION, INC.	+3.27%	+3.76%	+25.05%	+42.80%	31.91B
REVOLUTION MEDICINES, INC.	+2.37%	+50.22%	+181.77%	+298.64%	22.65B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-26.23%	-1.48%	+24,147.39%	+4,036.79%	21.81B
MEDPACE HOLDINGS, INC.	+1.54%	-0.08%	+72.84%	+166.20%	16.88B
EUROFINS SCIENTIFIC SE	+1.98%	+6.28%	+49.19%	+13.43%	14.8B
ICON PUBLIC LIMITED COMPANY	+1.74%	-9.03%	-15.92%	-18.35%	13.76B
Average	-1.26%	+6.72%	+2,467.07%	+470.69%	25.55B
Weighted average by Cap.	-0.96%	+7.37%	+2,106.03%	+398.29%

	2025 *	2026 *
Net sales	53.36M 45.85M 42.76M 39.73M 74.14M 4.82B 79.94M 492M 193M 2.3B 200M 196M 8.49B	47.38M 40.71M 37.97M 35.28M 65.83M 4.28B 70.98M 436M 172M 2.04B 178M 174M 7.54B
Net income	-295M -253M -236M -220M -410M -26.62B -442M -2.72B -1.07B -12.72B -1.11B -1.08B -46.92B	-333M -286M -267M -248M -463M -30.11B -499M -3.07B -1.21B -14.39B -1.25B -1.22B -53.07B
Net Debt	-867M -745M -695M -646M -1.2B -78.32B -1.3B -7.99B -3.14B -37.43B -3.25B -3.19B -138B	-772M -663M -618M -575M -1.07B -69.68B -1.16B -7.11B -2.79B -33.3B -2.89B -2.83B -123B